Search Results

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Apollo Endosurgery, Inc. (Nasdaq: APEN) for a cash price of $10 per share, reflecting an enterprise value of approximately $615 million.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the third quarter ended September 30, 2022 and recent corporate highlights.

Apollo Endosurgery, Inc. announced today that the MERIT trial, published in The Lancet earlier this year (1), was selected as 2022 Top Story in Gastroenterology.

Apollo Endosurgery, Inc., a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced financial results for the second quarter ended June 30, 2022 and recent corporate highlights.

Apollo Endosurgery, Inc. today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.

Apollo Endosurgery, Inc. announced that Sharon O’Keefe has joined the company’s Board of Directors, effective July 6, 2022.

Apollo Endosurgery, Inc. announced today the marketing authorization of the Apollo ESG TM, Apollo ESG Sx TM, Apollo REVISE TM and Apollo REVISE Sx TM Systems through the U.S. Food and Drug Administration’s (FDA) De Novo Classification process, a rigorous pre-market review pathway for low-to moderate-risk devices without a predicate.

Apollo Endosurgery, Inc. announced today the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial (MERIT) Study in The Lancet .